Sind die Gen- oder Stammzelltherapie eine therapeutische Option?

摘要: The aim of cardiovascular gene and stem cell therapy concepts is regeneration vascular myocardial cells in ischaemically damaged areas. Despite the wealth more or less valid study results, two main directions for clinical investigation can be distinguished. Gene with angiogenic growth factors form repetitive intramuscular injections naked plasmid DNA (pDNA) simple to perform principally applied investigations field peripheral arterial occlusive disease (“therapeutic angiogenesis”). Anumber parallel phase II studies nonviral pDNA fibroblast factor-1 (FGF-1) are ongoing USA Europe (TALISMAN studies). In ischaemic heart cell-based showing first results. Adult obtained by bone marrow puncture ex-vivo expansion blood circulating also deriving from patient’s marrow. After intracoronary administration what hoped intensified neovascularisation myocardium through release mononuclear cells, infarcted transdifferentiation mesenchymal into cells. this context German multicentre Transplantation Of adult Progenitor Cells Ischaemic Heart Disease (TOPCARE-AMI study) Bone Marrow Transfer Enhance ST-Elevation Infarct Regeneration (BOOST will shortly widen our knowledge still further.